Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;110(2):661-667.
doi: 10.1111/apa.15522. Epub 2020 Sep 30.

Golimumab in adolescents with Crohn's disease refractory to previous tumour necrosis factor antibody

Judith Pichler  1 , Nima Memaran  1 , Wolf Dietrich Huber  1 , Christoph Aufricht  1 , Bettina Bidmon-Fliegenschnee  1
Affiliations

Golimumab in adolescents with Crohn's disease refractory to previous tumour necrosis factor antibody

Judith Pichler et al. Acta Paediatr. 2021 Feb.

Abstract

Aim: Anti-tumour necrosis factor (TNF)-α drugs are effective treatments for the management of moderate/severe Crohn's disease (CD), but treatment failure is common. In the treatment of paediatric CD, there are no data about the use of a third introduced subcutaneous TNF antibody golimumab.

Methods: We evaluated the efficacy of golimumab for adolescents with moderate/severe CD. Retrospective analyses were done in all 7 (5 girls) adolescents who received golimumab at a median age of 17 years for a median of 7.2 months. Paediatric Crohn's disease activity index (PCDAI), full blood count, inflammatory markers, use of corticosteroids and adverse events were recorded.

Results: With golimumab, 5 of the 7 children were PCDAI responders and 2 entered remission (PCDAI <10). Faecal calprotectin was significantly reduced after 4 weeks compared to baseline. Out of five children, steroid withdrawal was possible in one and steroid reduction in two cases. There were no serious side effects.

Conclusion: In moderate/severe CD, golimumab induced clinical remission with PCDAI response. Golimumab may be an effective rescue therapy in refractory CD.

Keywords: Crohn's disease; adolescents; clinical response; golimumab.

PubMed Disclaimer

Conflict of interest statement

There is no financial or personal relationship with other people or organisations that could inappropriately influence this work. There were no financial or personal relationships with any company or organisation sponsoring the research at the time the research was done.

Figures

FIGURE 1
FIGURE 1
Effect of GLM on PCDAI
See this image and copyright information in PMC

References

    1. Parashette KR, Makam RC, Cuffari C. Infliximab therapy in pediatric Crohn's disease: a review. Clin Exp Gastroenterol. 2010;3:57‐63. - PMC - PubMed
    1. Griffiths AM, Nguyen P, Smith C, et al. Growth and clinical course of children with crohn's disease. Gut. 1993;34(7):939‐943. - PMC - PubMed
    1. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6‐mercaptopurine and prednisone in children with newly diagnosed crohn's disease. Gastroenterology. 2000;119(4):895‐902. - PubMed
    1. Bell SJ, Kamm MA. Review article: the clinical role of anti‐TNFalpha antibody treatment in crohn’s disease. Aliment Pharmacol Ther. 2000;14(5):501‐514. - PubMed
    1. Nicholls S, Stephens S, Braegger CP, et al. Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J Clin Pathol. 1993;46(8):757‐760. - PMC - PubMed